Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Inclusion Criteria:

* Patients must be platinum resistant
* Patients will be included in the study based on the following criteria:

  * No prior anthracycline use
  * PS less or equal 2
  * Lab values within certain limits (ANC greater 1000, platelets greater 100,000; ALT, AST 2 time ULN, creatinine less 2.0)
  * No more than 3 prior chemotherapy regimens, only 2 of which can have included platinum-containing regimens
  * Use of effective means of contraception in subjects of child-bearing potential

Exclusion Criteria:

1. Disease-Specific Exclusions:

   * Evidence of complete or partial bowel obstruction
   * Need for IV hydration or TPN
   * Greater 2 prior abdominal surgeries
   * History of gastrointestinal perforation
   * Gastrointestinal perforation due to any other cause within the last 6 months
2. General Medical Exclusions:

   * Inability to comply with study and/or follow-up procedures
   * Life expectancy of less than 12 weeks
   * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study
3. Avastin-Specific Exclusions

   * Inadequately controlled hypertension (defined as systolic blood pressure 150 and/or diastolic blood pressure greater 100 mmHg on antihypertensive medications)
   * Any prior history of hypertensive crisis or hypertensive encephalopathy
   * New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)
   * History of myocardial infarction or unstable angina within 6 months prior to study enrollment
   * History of stroke or transient ischemic attack within 6 months prior to study enrollment
   * Known CNS disease
   * Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
   * Symptomatic peripheral vascular disease
   * Evidence of bleeding diathesis or coagulopathy
   * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
   * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
   * History of abdominal fistula, or intra-abdominal abscess within 6 months prior to study enrollment
   * Serious, non-healing wound, ulcer, or bone fracture
   * Proteinuria at screening as demonstrated by either:

     * Urine protein:creatinine (UPC) ratio 1.0 at screening OR
     * Urine dipstick for proteinuria greater or equal 2plus (patients discovered to have greater or equal 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate less or equal 1g of protein in 24 hours to be eligible)
   * Known hypersensitivity to any component of Avastin
   * Pregnant (positive pregnancy test) or lactating. No effective means of contraception (men and women) in subjects of child-bearing potential